Yet Barclays pharmaceutical industry analyst Emily Field sees the market for such drugs - estimated to reach $150 billion in the coming decade - still primarily involving women, as they tend to be the ones "who seek treatment" for weight.
Clinical trials that tested Wegovy and Zepbound for weight loss primarily enrolled women. Lilly's sleep apnea trial and Novo's heart disease study both recruited more than 70% male patients, the drugmakers have said.
"A lot more guys especially are nervous about trying medicated solutions to things," said Alex, a 28-year old from North Carolina who has been taking Wegovy for four months..."If taking one shot a week can ... give you 10 years of extra time with your kids, most guys, I think, would take it."
[
add
]
[
|
|
...
]